C. Sawyers

Molecular Biology · 2001–2024

A researcher in the Science corpus: 40 papers; trusts 4 researchers and is trusted by 28 researchers here, as inferred from the citation graph.

Subfields

Whom C. Sawyers trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. Bell
  2. William Pao
  3. D. Haber
  4. J. Settleman
  5. Brian J. Druker
  6. W. Kaelin

Who trusts C. Sawyers overall

  1. A. Arora
  2. E. Scholar
  3. H. Shigematsu
  4. Berthold Huppertz
  5. Brian J. Druker
  6. Paul Geeleher
  7. William Pao
  8. Vardhman K. Rakyan
  9. Philip A Watson
  10. D. Altieri

Papers from C. Sawyers's perspective

Ordered by how strongly the researchers C. Sawyers trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR (Proceedings of the National Academy of Sciences of the United States of America)
  2. Molecular portraits of human breast tumours (Nature)
  3. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. (New England Journal of Medicine)
  4. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. (New England Journal of Medicine)
  5. Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex (Science)
  6. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways (Nature Medicine)
  7. S6K1−/−/S6K2−/− Mice Exhibit Perinatal Lethality and Rapamycin-Sensitive 5′-Terminal Oligopyrimidine mRNA Translation and Reveal a Mitogen-Activated Protein Kinase-Dependent S6 Kinase Pathway (Molecular and Cellular Biology)
  8. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib (PLoS Medicine)
  9. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer (Nature Medicine)
  10. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. (Journal of Clinical Oncology)

Their papers